Show simple item record

dc.contributor.authorSillanpää, Elina
dc.contributor.authorPalviainen, Teemu
dc.contributor.authorRipatti, Samuli
dc.contributor.authorKujala, Urho M.
dc.contributor.authorKaprio, Jaakko
dc.date.accessioned2022-01-18T13:38:38Z
dc.date.available2022-01-18T13:38:38Z
dc.date.issued2022
dc.identifier.citationSillanpää, E., Palviainen, T., Ripatti, S., Kujala, U. M., & Kaprio, J. (2022). Polygenic Score for Physical Activity Is Associated with Multiple Common Diseases. <i>Medicine and Science in Sports and Exercise</i>, <i>54</i>(2), 280-287. <a href="https://doi.org/10.1249/MSS.0000000000002788" target="_blank">https://doi.org/10.1249/MSS.0000000000002788</a>
dc.identifier.otherCONVID_101591969
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/79402
dc.description.abstractIntroduction Genetic pleiotropy, in which the same genes affect two or more traits, may partially explain the frequently observed associations between high physical activity (PA) and later reduced morbidity or mortality. This study investigated associations between PA polygenic risk scores (PRSs) and cardiometabolic diseases among the Finnish population. Methods PRSs for device-measured overall PA were adapted to a FinnGen study cohort of 218,792 individuals with genome-wide genotyping and extensive digital longitudinal health register data. Associations between PA PRS and body mass index (BMI), diseases, and mortality were analysed with linear and logistic regression models. Results A high PA PRS predicted a lower BMI (β -0.025 kg/m2 per one standard deviation (SD) change in PA PRS, SE 0.013, p = 1.87x10-80). The PA PRS also predicted a lower risk for diseases that typically develop later in life or not at all among highly active individuals. A lower disease risk was systematically observed for cardiovascular diseases [odds ratio, OR per 1 SD change in PA PRS 0.95, p = 9.5*10-19) and, for example, hypertension [OR 0.93, p = 2.7*10-44), type 2 diabetes (OR 0.91, p = 4.1*10-42), and coronary heart disease (OR 0.95 p = 1.2*10-9). Participants with high PA PRS had also lower mortality risk (OR 0.97, p = 0.0003). Conclusions Genetically less active persons are at a higher risk of developing cardiometabolic diseases, which may partly explain the previously observed associations between low PA and higher disease and mortality risk. The same inherited physical fitness and metabolism related mechanisms may be associated both with PA levels and with cardiometabolic disease risk.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherLippincott Williams & Wilkins; American College of Sports Medicine
dc.relation.ispartofseriesMedicine and Science in Sports and Exercise
dc.rightsCC BY-NC-ND 4.0
dc.titlePolygenic Score for Physical Activity Is Associated with Multiple Common Diseases
dc.typeresearch article
dc.identifier.urnURN:NBN:fi:jyu-202201181171
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.oppiaineGerontologia ja kansanterveysfi
dc.contributor.oppiaineLiikuntalääketiedefi
dc.contributor.oppiaineGerontology and Public Healthen
dc.contributor.oppiaineSports and Exercise Medicineen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.format.pagerange280-287
dc.relation.issn0195-9131
dc.relation.numberinseries2
dc.relation.volume54
dc.type.versionpublishedVersion
dc.rights.copyright© 2021 the Authors
dc.rights.accesslevelopenAccessfi
dc.type.publicationarticle
dc.subject.ysosairastavuus
dc.subject.ysofyysinen aktiivisuus
dc.subject.ysosydän- ja verisuonitaudit
dc.subject.ysoriskitekijät
dc.subject.ysogeneettiset tekijät
dc.subject.ysokohorttitutkimus
dc.subject.ysokuolleisuus
dc.subject.ysopitkittäistutkimus
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p3556
jyx.subject.urihttp://www.yso.fi/onto/yso/p23102
jyx.subject.urihttp://www.yso.fi/onto/yso/p9886
jyx.subject.urihttp://www.yso.fi/onto/yso/p13277
jyx.subject.urihttp://www.yso.fi/onto/yso/p21661
jyx.subject.urihttp://www.yso.fi/onto/yso/p25606
jyx.subject.urihttp://www.yso.fi/onto/yso/p5003
jyx.subject.urihttp://www.yso.fi/onto/yso/p14610
dc.rights.urlhttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.relation.doi10.1249/MSS.0000000000002788
jyx.fundinginformationThe FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd., Biogen MA Inc., Celgene Corporation, Celgene International II Sàrl, Genentech Inc., Merck Sharp & Dohme Corp., Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, and Novartis AG
dc.type.okmA1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

CC BY-NC-ND 4.0
Except where otherwise noted, this item's license is described as CC BY-NC-ND 4.0